The Growing Radioactive Tracer Market is driven by increasing prevalence of chronic diseases Market Drivers The increasing geriatric population globally is a significant factor fueling the Radioactive Tracer Market Growth. Older adults above 65 years of age have higher risks of medical conditions like cancer, heart disease, and neurological disorders. The rising senior population will augment the need for nuclear medicine diagnostics and subsequently radioactive tracer demand. According to the United Nations, the geriatric population of over 65 is projected to reach 1.5 billion by 2050. Get More Insights: Radiological Tracer Market (https://fortunetelleroracle.com/health-care/radioactive-tracer-market-witnesses-significant-growth-due-to-advancements-in-nuclear-medicine-951855#google_vignette )

The Expanding Human Immunoglobulin (pH4) for Intravenous Injection Market One of the key drivers of the Human Immunoglobulin (pH4) for Intravenous Injection Market Demand is the rising incidence of chronic diseases worldwide. Conditions like cancer, cardiovascular diseases, neurological disorders and diabetes have significantly increased in prevalence. To sustain strong growth amid prevailing geopolitical uncertainties, companies operating in the Human Immunoglobulin (pH4) for Intravenous Injection Market Size and Trends need to devise effective strategies. Diversifying sourcing networks and establishing local manufacturing facilities can help immunoglobulin providers reduce dependence on major global trade routes and avoid sudden supply disruptions. Get More Insights: Human Immunoglobulin (pH4) for Intravenous Injection Market (https://medium.com/@avantika.cmi/the-growing-human-immunoglobulin-ph4-for-intravenous-injection-market-is-anticipated-to-witness-0fdf57758ce7 )

Expanding Access to Safe Swallowing Therapies Will Drive the Dysphagia Management Market The dysphagia management market consists of products and therapies that aim to aid patients suffering from swallowing disorders or dysphagia. Some key products in this market include feeding tubes, impaired swallowing assessment systems, oral nutritional supplements, and throat dilation devices. Rising prevalence of neurological disorders and cancers is a major factor driving the Dysphagia Management Market Growth. According to the WHO, cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Get more insights: Dysphagia Management Market (https://www.newswirestats.com/dysphagia-management-market-analysis/) #CoherentMarketInsights #DysphagiaManagementMarket #Drugs #FeedingTubes #OropharangealDysphagia #EsophagealDysphagia #HospitalsPharmacies #RetailPharmacies

Long-Acting Drug Delivery: A Novel Pharmacological Strategy to Deliver Therapeutic Modalities LADD has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. These novel systems circumvent the limitations of conventional drug delivery system, such as multiple dosing frequency, fluctuating plasma levels, high toxicity levels and poor patient compliance. Principles and Strategies associated with Long-Acting Drug Delivery Lately, many technologies are being explored to develop long-acting drug in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The LADD technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery system. Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. What are the Benefits of Outsourcing to Contract Service Providers (CDMOs / CDOs / CMOs)? One of the critical factors associated with the development of long-acting drugs is the selection of drug therapeutic window and its absorption characteristics. It also encompasses the quantitative determination of drug metabolism and pharmacokinetic (DMPK) properties. In addition, the formulation of these drugs is a complex process, especially if there is inclusion of highly potent molecules. Some of the other challenges include aseptic manufacturing, terminal sterilization, suitable characterization methods, lack of GMP-certified facilities and specialized equipment. Owing to the advanced LADD technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability on stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome. Bottom Line Keeping every trend in mind, Roots Analysis has provided complete information on market trends in long-acting drug delivery domain, which has some of the very recent and precise activities listed for the clients to help them make better decisions in its report titled, Long-Acting Drug Delivery Technologies and Services Market, 2023-2035. To find answers to key decision-making question and to know further about the market forecast analysis, highlighting the likely growth of the long-acting drug delivery technologies and services market, for the time period 2023-2035. For additional details, please visit https://www.rootsanalysis.com/blog/long-acting-drug-delivery-technologies/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

SARM1 Inhibitors: A Novel Approach Against Neurodegenerative Disorders Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide. Given the encouraging research outcomes, the players in this domain have received more than USD 10 million in grants, since 2014, from the various private and public organizations. Additionally, several patents related to SARM1 targeting therapies have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 targeting therapeutics market is anticipated to witness substantial growth in the mid to long-term. Current Market Trend At present, several companies worldwide have taken initiatives to develop SARM1 inhibitors for targeting multiple neurological disorders, including multiple sclerosis and amyotrophic lateral sclerosis. The market is characterized by a mix of well-established and small firms. Currently, their pipeline features both biologics and small molecules drugs, which are being evaluated in preclinical and discovery stages. Strong Intellectual Property Portfolio Over the years, the number of patents filed for SARM1 inhibitors has increased gradually; majority of the patents have been filed / granted in 2021. In addition, most of the patents in this domain are patent applications (96%), followed by granted patents (3%). Future opportunities for SARM1 Inhibitors Currently, there are no potential treatment options that target axonal degeneration associated disorders. Across various studies, SARM1 inhibitors have demonstrated the potential to treat multiple neurodegenerative disorders; once approved, these therapies are likely to capture a sizeable market share in the coming future. Further, we expect the first product to be commercially launched in 2033; post that, the market is expected to grow at an annualized rate of 102%. For additional details, please visit https://www.rootsanalysis.com/blog/sarm1-inhibitors-market/ or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

LONG-ACTING DRUG DELIVERY TECHNOLOGIES AND SERVICES Long-acting drug delivery has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. The long-acting delivery of drug candidates confers several advantages, such as improved patient compliance, reduced dosage requirement, better medication adherence, decrease in failure risk due to inconsistent usage and more convenience to patients. In addition, long acting drug delivery formulations can improve the chemical stability, solubility and polymorphic transformation issues of the active pharmaceutical ingredients. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/long-acting-drug-delivery-market/request-sample.html Lately, many technologies are being explored to develop long-acting drugs in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The long-acting drug delivery technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery system. Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. Long-acting formulations are more patient compliant, in terms of sharp reduction in the dosing regimen. These drugs are administered infrequently (ranging from once weekly to yearly) owing to the prolonged drug release after a single shot. The technological advancements for the long-acting profile of the drugs (small molecules, peptides, biologics) have led to the rise in number of novel therapeutics in the market along with the growing number of long-acting molecules in the clinical development pipeline. Of late, the demand for the availability of long-acting vaginal rings as multipurpose prevention technologies for women is also surfacing. Further, the pharmaceutical industry is extensively focusing on the development of long-acting injectables for protein-based drugs and multidrug therapies. Moreover, the potential of long acting injectables is being explored in several debilitating chronic diseases, such as Alzheimer’s, Parkinson’s disease, blindness and HIV. Owing to the advanced LADD technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability on the stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome. For additional details, please visit https://www.rootsanalysis.com/reports/long-acting-drug-delivery-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com